Verano Holdings (VRNO) Non Operating Investment Income (2022)
Verano Holdings (VRNO) posted quarterly Non Operating Investment Income of $175000.0 for Q3 2022, up 202.34% quarter-over-quarter from -$171000.0 in Q2 2022.
Verano Holdings (VRNO) Non Operating Investment Income (2022) Analysis & Trends
Verano Holdings (VRNO) has reported Non Operating Investment Income for 1 consecutive years, with $175000.0 the latest figure, recorded in Q3 2022.
- In Q3 2022, Non Operating Investment Income changed N/A year-over-year to $175000.0; the TTM figure through Jun 2023 stood at $175000.0 (up 105.23% YoY), while the FY2022 annual figure was $14.1 million, changed N/A from the prior year.
- Non Operating Investment Income grew to $175000.0 in Q3 2022 per VRNO's latest filing, from -$171000.0 in the prior quarter.
- Across five years, Non Operating Investment Income topped out at $175000.0 in Q3 2022 and bottomed at -$3.2 million in Q1 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.81 Bn | 42.84 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.29 Bn | 39.63 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.59 Bn | 29.91 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.67 Bn | 22.88 Bn | 5.10 Bn | - |
| 5 | United Therapeutics | 22.24 Bn | 19.58 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.79 Bn | 17.91 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.71 Bn | 15.32 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 12.09 Bn | 11.56 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | - |
| 10 | Verano Holdings | 445.39 Mn | 360.20 Mn | 99.70 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | 175,000.00 |
| Sep 30, 2022 | 175,000.00 |
| Jun 30, 2022 | -171,000.00 |
| Jun 30, 2022 | -171,000.00 |
| Mar 31, 2022 | -3.18 Mn |
| Mar 31, 2022 | -3.18 Mn |